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Clinical, Serologic, and Parasitologic Follow-Up after Long-Term
Allopurinol Therapy of Dogs Naturally Infected with
Leishmania infantum
Tanja Cavaliero, Pierre Arnold, Alexander Mathis, Tony Glaus, Regine Hofmann-Lehmann, and Peter Deplazes
Canine leishmaniasis usually is treated with antimony compounds, but frequent relapses, adverse effects, high costs, and devel-
opment of resistance to long-term antimonial therapy emphasize the importance of searching for alternative antileishmanial drugs.
Allopurinol was used at a dosage of 10 mg/kg/day PO to treat 10 dogs naturally infected with Leishmania infantum for a period
of 2–24 months. Nine dogs recovered within 2–6 months of chemotherapy, and no relapses were observed during the treatment
of up to 20 months. However, 3 of 4 dogs relapsed after treatment was discontinued. These dogs again recovered clinically when
therapy was resumed. Parasite-specific immunoglobulin concentrations (IgG2) were high in all dogs before therapy and remained
high even in clinically cured dogs during or after therapy. On the other hand, specific IgG1 reactions, which have been shown to
be detectable in symptomatic animals, persisted in 7 dogs for long periods after clinical recovery. Three of these dogs relapsed
within 2–4 weeks after interrupting therapy. However, 1 dog with no detectable specific IgG1 reaction at the end of therapy did
not relapse in the following 4 months. Parasites could be detected in 8 of 9 dogs after clinical improvement by in vitro cultivation
or polymerase chain reaction (PCR) testing of lymph node aspirates. In 4 of these dogs, parasites also were detected in blood
samples by PCR. Hence, these clinically cured dogs must be regarded as reservoirs of Leishmania and allopurinol cannot be
recommended in endemic areas.
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Leishmaniasis is a globally widespread disease.1 In Med-iterranean countries, it affects humans and dogs2,3 and
is considered to be the most common opportunistic parasitic
infection among human immunodeficiency virus-positive
persons.4 In Mediterranean countries, dogs are the main res-
ervoir host for visceral leishmaniasis caused by the proto-
zoan parasite Leishmania infantum, which is transmitted be-
tween vertebrate hosts by female sandflies of the genus
Phlebotomus. The incubation period in dogs is variable,
ranging from 3 months to several years,5 and most dogs
develop a chronic disease with anemia, hypergammaglob-
ulinemia, generalized lymphadenopathy, skin lesions, epi-
staxis, and chronic renal failure with eventual death.
In endemic areas, veterinarians should inform dog own-
ers that infected asymptomatic, nontreated and treated dogs
may be a source of infection for sandflies even after suc-
cessful clinical therapy.2,6–8 Therefore, from an epidemio-
logic point of view, infected dogs should be euthanized
because elimination of infection is not achieved by che-
motherapy. The most commonly used drugs are pentavalent
antimonial compounds such as meglumine antimoniate
(Glucantime, Rhoˆne-Me´rieux, Lyon, France) and sodium
stibogluconate (Pentostam, Wellcome, Dartford, UK) but
frequent relapses, severe adverse effects, high cost, and de-
velopment of resistance must be considered.5,9–13
Allopurinol, a purine analogue, has been used for treat-
ment of visceral leishmaniasis in humans, alone or com-
bined with the previously mentioned drugs with satisfactory
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results.14–18 Allopurinol is metabolized by the parasites to
nucleotides and aminated to analogues of adenine nucleo-
tides causing breakdown of RNA and halting protein syn-
thesis.19
The therapeutic potential of allopurinol for the treatment
of canine leishmaniasis alone or in combination with anti-
monials recently has been reported.2,20–24 However, despite
clinical cure, relapses have been observed, and parasite
clearance in clinically cured dogs treated solely with allo-
purinol has not been investigated.
The aim of this study was to test the efficacy of long-
term allopurinol treatment in dogs with naturally acquired
leishmaniasis with respect to clinical cure and parasite elim-
ination, as assessed by serology, in vitro cultivation of pro-
mastigote stages of the organism, and polymerase chain re-
action (PCR).
Materials and Methods
Dogs
Ten dogs, 6 females and 4 males, of different breeds and ranging
in age from 1 to 10 years were included in this study. Six of these
dogs acquired infection in their country of origin (Spain and Italy) and
4 dogs by visiting countries where leishmaniasis is endemic (France,
Greece, and Italy).
Specific Antibody Detection
The specific detection of immunoglobulins (IgG1 and IgG2) against
an extract of soluble L infantum promastigote antigen was performed
by enzyme-linked immunosorbent assay (ELISA).25 The same ELISA
was used for the detection of IgG gamma parasite-specific antibodies,
modifying the conjugate only (goat anti-dog IgGg, [Kirkegaard and
Perry Lab Inc, Gaithersburg, MD] conjugated to alkaline phosphatase,
diluted 1:1,000). The lower limit of detection of the 3 different ELISA
assays was taken as the mean optical density value (A405 nm) plus 3
standard deviations in serum of 50 healthy dogs from Switzerland.
Parasitologic Diagnosis
Parasitologic diagnosis was made every 1 or 2 months by in vitro
cultivation of lymph node aspirates and detection of promastigote stag-
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Table 1. Clinical course of leishmaniasis in 6 naturally infected dogs after treatment with allopurinol.
Dog No. Monthsa Clinical Symptoms Parasite Detectionb
1 0
2
3
9
Generalized alopecia, skin ulcers
Improvement of hair coat
Healthy
Healthy
LN/in vitro1, B/PCR1
B/PCR2
B/PCR2
B/PCR2
2 0
1
2
4
6
19
Lymphadenopathy, skin lesions on head and ears
Improvement of skin lesions
Healthy
Healthy
Healthy
Healthy
B/PCR2
LN/in vitro2, LN/PCR2, B/PCR2
B/PCR2
B/PCR1
B/PCR2
LN/in vitro2, LN/PCR2, B/PCR2
3 0
2
5
7
22
Epistaxis, skin lesions on head and ears
Healthy
Healthy
Healthy
Healthy
LN/in vitro1, B/PCR1
LN/in vitro1, B/PCR2
LN/in vitro2, LN/PCR1, B/PCR1
LN/in vitro2, LN/PCR2, B/PCR2
LN/in vitro1, B/PCR2
7 0
2
3
6
8
Epistaxis, lymphadenopathy
Anemia
Healthy
Slight diarrhea
Gastroenteritis and vomiting
LN/in vitro1, B/PCR1
B/PCR1
B/PCR1
B/PCR1
Not done
8 0
2
3
7
9
Skin lesions on ears and nose
Improvement of lesions
Healthy
Healthy
Healthy
LN/in vitro1, B/PCR1
LN/in vitro1, B/PCR1
LN/in vitro1, B/PCR2
LN/in vitro1, B/PCR2
LN/in vitro2, LN/PCR2, B/PCR2
9 0
1
2
Renal failure, lymphadenopathy
Fever, anemia, renal failure
Anemia, severe renal failure, euthanasia
LN/in vitro1, B/PCR1
B/PCR1
LN/in vitro1, B/PCR2
LN, lymph node; B, blood; PCR, polymerase chain reaction.
a After start of therapy.
b By in vitro cultivation and/or PCR.
es12 or by PCR of lymph node aspirates or heparinized blood.26 In
cases proven positive by in vitro cultivation, only blood samples were
tested by PCR. If in vitro cultivation was either negative or could not
be evaluated because of heavy bacterial contamination, samples also
were tested for the presence of parasites by PCR.
Chemotherapy
Dogs were treated PO with allopurinol (Allopur, GEA, Frederiks-
berg, Denmark) at a dosage of 10 mg/kg/day. The period of treatment
varied between 2 to 24 months. After remission of clinical signs, we
intended to stop chemotherapy in order to see whether relapses would
occur. Being aware that the dogs could still be infected with the par-
asite despite their healthy appearance, the owners of dogs 1, 2, 3, 7,
and 8 did not agree to interruption of therapy. Treatment was discon-
tinued from months 20 to 21 in dog 4 and from months 5 to 6 in dog
5. Dog 6 had been treated before with meglumine antimoniate but
relapsed and therefore was treated with allopurinol. The owner of dog
6 interrupted therapy after 14 months for 2 weeks. Therapy was
stopped after 4 months in dog 10.
Follow-Up Examinations
Dogs were presented for follow-up investigations every 1–2 months
at the beginning of the study, but at longer intervals later with clinical
improvement. Details of the treatment course are summarized in Tables
1, 2.
Clinicopathologic data included CBC, serum biochemistry, and uri-
nalysis. In addition, globulins were analyzed for their g and b frac-
tions.
The dogs’ serologic responses to therapy were monitored by mea-
suring specific IgG (gamma specific), IgG1, and IgG2 by ELISA, and
the presence of parasites was assessed by periodic in vitro cultivation
and PCR of lymph node aspirates and blood.
Results
Clinical Response
Clinical follow-up during allopurinol therapy is depicted
in Tables 1, 2. At the beginning of the study, all dogs had
clinical signs associated with leishmaniasis, but with dif-
ferent severity. Four dogs had localized skin lesions on the
head, ears, and nose and 4 dogs had generalized skin le-
sions. Lymphadenopathy was observed in 6 dogs. Two dogs
had recurrent episodes of epistaxis, and 1 dog had acute
nephritis accompanied by generalized lymphadenopathy.
Nine of the 10 dogs recovered clinically after treatment for
2–6 months and no relapses occurred during long-term
treatment. Dogs 4, 5, and 6 relapsed after interruption of
their therapy. The relapses were characterized by the oc-
currence of skin lesions and enlargement of lymph nodes.
Dogs 4 and 6 recovered again when therapy was resumed.
No further information is available about dog 5. Therapy
of dog 10 was stopped after 4 months and the animal re-
332 Cavaliero et al
Table 2. Clinical course of leishmaniasis in 4 dogs before and after interruption of treatment with allopurinol.
Dog No. Monthsa Clinical Symptoms Parasite Detectionb
4c 0
2
3
5
7
11
21
24
Hyperkeratosis, lymphadenopathy
Improvement of skin lesions, smaller lymph nodes
Healthy
Healthy
Healthy
Healthy
Relapsed
Healthy
LN/in vitro1, B/PCR1
LN/in vitro1, B/PCR2
B/PCR2
B/PCR2
LN/in vitro1, B/PCR1
LN/in vitro1, B/PCR2
LN/in vitro1, B/PCR1
LN/in vitro1, B/PCR2
5d 0
1
3
4
6
Lymphadenopathy, hyperkeratosis, skin ulcers
Improvement of skin lesions
No skin lesions, lymphadenopathy
Healthy
Relapsed
LN/in vitro1, B/PCR2
Not done
LN/in vitro1, B/PCR2
LN/in vitro2, LN/PCR2, B/PCR2
LN/in vitro1, B/PCR1
6e 0
2
6
8
14
20
Alopecia, skin ulcers
Improvement of skin lesions
Healthy
Healthy
Relapsed
Healthy
LN/in vitro1, B/PCR2
B/PCR2
Not done
LN/in vitro2, LN/PCR2, B/PCR2
Not done
LN/in vitro1
10f 0
2
3
5
7
9
Skin lesions on head, lymphadenopathy
Few skin lesions and lymphadenopathy
Healthy
Healthy
Healthy
Healthy
LN/in vitro1
LN/in vitro2, LN/PCR1, B/PCR1
B/PCR2
LN/in vitro1, B/PCR2
B/PCR2
B/PCR2
LN, lymph node; B, blood; PCR, polymerase chain reaction.
a After start of therapy.
b By in vitro cultivation and/or PCR.
c Therapy discontinued between months 20 and 21.
d Therapy discontinued between months 5 and 6.
e Therapy interrupted during month 14 for 2 weeks.
f Therapy discontinued after 4 months.
mained healthy for 5 months until the end of the study.
Dog 9 was euthanized 2 months after beginning therapy
because of severe renal failure. Dog 7 had no more char-
acteristic signs of leishmaniasis after 8 months of treatment
but suffered from diarrhea and vomiting. Dogs 1, 2, and 9
had concomitant infections with Ehrlichia canis and dog 6
had concomitant infection with Dirofilaria repens.
Microcytic normochromic anemia was observed in dogs
5, 7, and 10 before therapy (data not shown). Despite clin-
ical improvement, anemia persisted in dogs 5 and 7 even
after 6 and 8 months of treatment, respectively. The he-
matologic values in dog 10 were normal 4 months after
beginning therapy.
Changes were observed in the concentrations of albumin,
b and g globulins, and total protein performed each 2
months (data not shown). All dogs had high concentrations
of globulins at the beginning of treatment. These concen-
trations decreased to normal (1.12–1.87 g/dL) in dogs 2, 8,
and 10 but remained high in dogs 1, 3, 4, 5, 6, 7, and 9
during therapy. After interruption of therapy, globulin con-
centrations tended to increase in dogs 4, 5, and 6.
At the beginning of treatment, albumin concentrations
were low in all dogs except dogs 4 and 6, which had normal
concentrations (3.22–4.21 g/dL). The concentration of al-
bumin increased during treatment to normal in dogs 1, 2,
3, 8, and 10 and remained below normal in dogs 5, 7, and
9. After interruption of therapy, the concentration of albu-
min decreased in dogs 5 and 6.
Hyperproteinemia was observed in all dogs at the begin-
ning of therapy. High total protein concentrations correlated
with the increase in g and b globulin concentrations during
treatment (data not shown).
No changes were observed in serum electrolyte concen-
trations.
Parasite-Specific Antibody Reactions
Parasite-specific (IgG1, IgG2, and IgG gamma specific)
antibody reactions during therapy were performed every 2
months (data not shown). The pretreatment concentrations
of IgG2 and IgG gamma parasite-specific antibodies were
high in all dogs. The concentrations of IgG2 in dogs 1, 2,
3, 4, 5, 6, 7, and 9 remained high or decreased only slightly
toward the end of therapy. The IgG2 response in dogs 8
and 10 differed from that of the other dogs by progressively
decreasing until the end of therapy, but remaining well
above the lower limit of detection of the assay. The IgG
gamma specific concentrations remained high and correlat-
ed with the results of the IgG2 ELISA. At the beginning
of therapy anti-leishmania IgG1 concentrations were above
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the lower limit of detection of the assay in all dogs except
dog 8. During therapy, IgG1 concentrations generally de-
creased but persisted near the lower limit of detection of
the assay in 7 dogs (dogs 1, 2, 3, 4, 5, 6, and 7) for long
periods despite clinical cure, excluding dog 4, which
showed values below the lower limit of detection of the
assay.
Parasite Detection
Leishmania infection was confirmed in all dogs before
or during chemotherapy by means of in vitro cultivation of
lymph node aspirates or PCR (Tables 1, 2). Before therapy,
Leishmania promastigote stages were detected by in vitro
cultivation of lymph node aspirates in 9 dogs. After clinical
cure, 9 (60%) of a total of 15 aspirations from 7 dogs were
positive for L infantum by in vitro cultivation. In 1 of the
6 negative samples, the presence of the parasite was con-
firmed by PCR of blood and lymph node aspirate. In 12
(57%) of 21 blood samples from dogs with clinical symp-
toms, before, during, and after interruption of treatment,
circulating Leishmania were detected by PCR, whereas
only 5 (19%) of 26 blood samples were positive in treated
asymptomatic dogs.
Discussion
Nine of 10 dogs responded well to the allopurinol ther-
apy at a dosage of 10 mg/kg/day, resulting in improvement
or clinical cure after 2–6 months. No apparent adverse ef-
fects were associated with treatment as assessed by clinical,
hematologic, and blood chemistry testing. Allopurinol has
been used in dogs at dosages of 15–30 mg/kg/day for 1–
10 months with clinical cure.20,23 Treatment with allopurinol
at 11 mg/kg/day for 4 months resulted in clinical cure, but
the dog relapsed 1 month later and was treated again with
15 mg/kg/day allopurinol for another 9 months. The dog
still was clinically healthy 19 months after allopurinol was
discontinued.24 However, parasitologic status of the cured
dogs was not thoroughly investigated in these studies. In
our study, relapses were observed in 3 of 4 dogs after long-
term therapy with allopurinol at 10 mg/kg/day was discon-
tinued for 2 weeks to 1 month. Based on recently published
results and the results of this study, we conclude that a
dosage of 10 mg/kg/day does not effectively eliminate the
parasite, even after long-term administration.
Despite the recovery and clinical cure of our patients,
parasites were detected in 8 of 9 dogs by means of in vitro
cultivation or PCR of lymph node aspirates or blood sam-
ples. Because blood samples were washed free of plasma
and subsequently depleted of erythrocytes, only intracel-
lular Leishmania stages within mononuclear cells were con-
centrated in samples used for PCR. Therefore, it is very
unlikely that free DNA or DNA from killed parasites was
amplified. The finding that clinically cured dogs that had
been treated daily with allopurinol still had circulating
Leishmania parasites in the blood as detected by PCR in-
dicates that such animals remain potential reservoirs of par-
asites.
From a diagnostic point of view, the sensitivity of the in
vitro cultivation of lymph node aspirates was lower in clin-
ically cured dogs. After therapy and remission of lymph-
adenopathy, popliteal lymph nodes were very small, and it
was difficult to obtain biopsy material. Therefore, errors in
collecting material as well as microbial contamination of
samples occur quite often and limit the value of in vitro
cultivation. PCR has proven to be a good alternative for
parasite detection in contaminated samples.
Compared to earlier studies of imported dogs with leish-
maniasis studied at the animal hospital in Zurich,9,12,25 mild
clinical signs were found in the dogs of this study, except
for dog 9. This probably is due to the fact that veterinarians
in Switzerland are becoming more familiar with the clinical
signs of leishmaniasis, resulting in earlier diagnosis. Fur-
thermore, dogs coming from endemic areas usually are se-
rologically tested with a sensitive ELISA for leishmaniasis.
The hypoalbuminemia and hyperglobulinemia5 typical of
leishmaniasis were also observed in our study. Albumin
concentrations tended to increase whereas globulin concen-
trations tended to decrease during treatment in all dogs that
responded to therapy. Even after clinical cure, albumin con-
centrations did not reach normal values in 2 dogs and glob-
ulins were still high in 6 dogs. In the 3 dogs that relapsed
after interruption of therapy, globulin concentrations tended
to increase again, and in 2 dogs albumin concentrations
tended to decrease. These results indicate that the immu-
nopathologic process persisted in most of the dogs although
the animals were clinically healthy before therapy was dis-
continued. This fact may explain the short time between
interruption of therapy and relapses, and serum globulin
concentrations should be assessed before discontinuing
therapy.
No correlation between the relatively high values of IgG2
or IgG gamma specific ELISA at the time of diagnosis and
during and after treatment, and the clinical condition of the
dogs could be established. High IgG2 ELISA values persist
several years after successful treatment with meglumine an-
timoniate in asymptomatic infected dogs.25 The IgG gamma
specific ELISA used in this study detected asymptomatic
infections in a seroepidemiologic study in Cyprus (Deplaz-
es, unpublished data). Therefore, IgG2 or IgG gamma spe-
cific ELISA as well as dot ELISA22 or direct agglutination
test27 do correlate with infection, but have no prognostic
value with respect to clinical cure of the dogs.
Anti-leishmania IgG1 concentrations were not as high at
the beginning of treatment as described by other authors.25
This result could have been be due to early diagnosis of
the disease in the dogs of this study. In 7 dogs, IgG1 an-
tibody results remained slightly positive (values near the
lower limit of detection of the assay) despite clinical cure.
After interrupting therapy in 3 of these dogs, all relapsed
within 1 month. However, dog 4 with no detectable specific
IgG1 reaction at the end of therapy did not relapse in the
following 4 months. Persistent IgG1 antibodies were de-
tected in chronically ill dogs and a decrease of these anti-
bodies to background concentration was observed in recov-
ered dogs after treatment with meglumine antimoniate.25
Therefore, the IgG1 ELISA seems to be of prognostic value
and useful to determine the appropriate time to discontinue
therapy, which might reduce the likelihood of eventual re-
lapses.
Allopurinol is efficient for the clinical treatment of ca-
nine leishmaniasis although further investigations are need-
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ed to determine optimal dosage and duration of treatment.
The drug is easy to administer, is inexpensive, and there
are few reports of adverse effects.28 Dogs that relapsed after
interruption of therapy with allopurinol were successfully
retreated with the same drug. No studies were performed
on development of resistance by Leishmania against allo-
purinol during the long period of drug administration. De-
spite clinical cure, dogs may have circulating parasites dur-
ing or after allopurinol treatment, and these animals may
remain active reservoirs of the disease. Clinically cured
dogs treated with allopurinol at a dosage of 10 mg/kg/day
must be regarded as potential parasite reservoirs. Conse-
quently, allopurinol cannot be recommended for the treat-
ment at this dosage, especially in endemic areas.
References
1. World Health Organization. Control of the leishmaniosis. Tech-
nical Report Series 1990:793.
2. Alvar J, Molina R, San Andres M, et al. Canine leishmaniosis:
Clinical, parasitological and entomological follow-up after chemother-
apy. Ann Trop Med Parasitol 1994;88:371–378.
3. Dedet JP, Lambert M, Pratlong F. Leishmaniosis and human im-
munodeficiency virus infections. Presse Med 1995;24:1036–1040.
4. Anonymous. The Leishmaniases and Leishmania/HIV co-infec-
tions. Inf Circ WHO Mediterr Zoon Control Cent 1997;40:11–13.
5. Slappendel RJ. Canine leishmaniosis. Vet Q 1988;10:1–17.
6. Hasibeder G, Dye C, Carpenter J. Mathematical modelling and
theory for estimating the basic reprodution number of canine leish-
maniosis. Parasitology 1992;105:43–53.
7. Molina R, Amela C, Nieto J, et al. Infectivity of dogs naturally
infected with Leishmania infantum to colonized Phlebotomus perni-
ciosus. Trans R Soc Trop Med Hyg 1994;88:491–493.
8. Berrahal F, Mary C, Roze M, et al. Canine leishmaniosis: Iden-
tification of asymptomatic carriers by polymerase chain reaction and
immunoblotting. Am J Trop Med Hyg 1996;55:273–277.
9. Kammermann-Lu¨scher B. Leishmaniose beim Hund. Schweiz
Arch Tierheilkd 1980;122:585–603.
10. Reusch C, Reiter I. Die importierte Hundeleishmaniose: Erfah-
rungen zu Klinik, Diagnostik und Therapie mit Na-Stibogluconat (Pen-
tostam). Tierarztl Prax 1987;15:305–310.
11. Gramiccia M, Gradoni L, Orsini S. Decreased sensitivity to
meglumine antimoniate (Glucantime) of Leishmania infantum isolated
from dogs after several courses of drug treatment. Ann Trop Med
Parasitol 1992;86:613–620.
12. Deplazes P, Arnold P, Skaggs J, et al. Parasitologische und Im-
munologische Verlaufskontrollen wa¨hrend und nach Chemotherapie
der Leishmaniose des Hundes. Schweiz Arch Tierheilkd 1992;134:85–
93.
13. Kraft W, Bauer G. Akute Pankreopathien als Nebenwirkungen
der Leishmaniose-Therapie. Kleintierpraxis 1994;39:309–310.
14. Kager PA, Rees PH, Wellde BT, et al. Allopurinol in the treat-
ment of visceral leishmaniosis. Trans R Soc Trop Med Hyg 1981;75:
556–559.
15. Jha TK. Evaluation of allopurinol in the treatment of kala-azar
occuring in North Bihar, India. Trans R Soc Trop Med Hyg 1983;77:
204–207.
16. Chunge CN, Gachihi G, Muigai R, et al. Visceral leishmaniosis
unresponsive to antimonial drugs. III. Succesful treatment using a
combination of sodium stibogluconate plus allopurinol. Trans R Soc
Trop Med Hyg 1985;79:715–718.
17. Legardere B, Chevallier B, Cheriet R. Le kala azar. Ann Pediatr
1992;39:159–164.
18. Terra L, Pellicano S, Allo M. Visceral leishmaniosis in patients
with HIV infection. Our experience. Minerva Med 1996;87:317–319.
19. Marr JJ, Berens RL. Pyrazolopyrimidine metabolism in the
pathogenic trypanosomatidae. Mol Biochem Parasitol 1983;7:339–
356.
20. Vercammen F, De Deken R, Kageruga P. First evaluation of the
use of allopurinol as a single drug for the treatment of canine leish-
maniosis. Vlaams Diergeneeskd Tijdschr 1995;64:208–214.
21. Liste F, Gascon M. Allopurinol in the treatment of canine vis-
ceral leishmaniasis. Vet Rec 1995;137:23–24.
22. Ferrer L, Aisa MJ, Roura M, et al. Serological diagnosis and
treatment of canine leishmaniosis. Vet Rec 1995;136:514–516.
23. Gothe R, Nolte I, Kraft W. Leishmaniose des Hundes in
Deutschland: Epidemiologische Fallanalyse und Alternative zur bish-
erigen kausalen Therapie. Tierarztl Praxis 1997;25:68–73.
24. Lester SJ, Kenyon JE. Use of allopurinol to treat visceral leish-
maniosis in a dog. J Am Vet Med Assoc 1996;209:615–617.
25. Deplazes P, Smith NC, Arnold P, et al. Specific IgG1 and IgG2
antibody responses of dogs to Leishmania infantum and other para-
sites. Parasite Immunol 1995;17:451–458.
26. Mathis A, Deplazes P. PCR and in vitro cultivation for detection
of Leishmania spp. in diagnostic samples from humans and dogs. J
Clin Microbiol 1995;33:1145–1149.
27. Vercammen F, De Deken R. Antibody kinetics during allopu-
rinol treatment in canine leishmaniosis. Vet Rec 1996;139:264.
28. Ling GV, Ruby AL, Harrold DR. Xanthine-containing urinary
calculi in dogs given allopurinol. J Am Vet Med Assoc 1991;198:
1935–1940.
